---
title: "Inventurus Knowledge Solutions Ltd (IKS) — Share Price, Financials & Analysis"
symbol: "IKS"
company: "Inventurus Knowledge Solutions Ltd"
canonical: "https://tapetide.com/stocks/IKS"
isin: "INE115Q01022"
nse_symbol: "IKS"
bse_code: "544309"
sector: "Information Technology"
industry: "IT Enabled Services"
market_cap_cr: 30131.68
generated_at: "2026-09-13T18:26:43.056Z"
---

# Inventurus Knowledge Solutions Ltd (IKS)

Canonical page: https://tapetide.com/stocks/IKS

## Company

- **NSE Symbol:** IKS
- **BSE Code:** 544309
- **ISIN:** INE115Q01022
- **Sector:** Information Technology
- **Industry:** IT Enabled Services
- **Macro Sector:** Information Technology
- **Stock Type:** EQUITY
- **Listed Since:** 2024-12-19
- **CEO:** Mr. Sachin K. Gupta
- **Employees:** 7530
- **Face Value:** ₹1
- **F&O Eligible:** No
- **Website:** ikshealth.com

## About

Incorporated in 2006, Inventurus Knowledge Solutions Ltd provides healthcare solutions through its care enablement platform[1]

## Latest Price

- **Price:** ₹1740.6
- **Change:** -43.1 (-2.42%)
- **Open:** ₹1783
- **Day High:** ₹1783
- **Day Low:** ₹1732.4
- **Previous Close:** ₹1783.7
- **Volume:** 83326
- **As Of:** 2026-09-11T10:27:11+00:00

## Key Fundamentals

Observed at 2026-09-11T04:34:59.373658Z.

- **Market Cap:** ₹30131.68 Cr
- **Classification:** Smallcap
- **P/E (reported):** 40
- **P/E (TTM):** 39.11
- **EPS (TTM):** ₹44.5
- **Book Value:** ₹163.1
- **Price to Book:** 10.92
- **Dividend Yield:** 0%
- **ROE:** 25.77%
- **ROCE:** 29.57%
- **Debt to Equity:** 0.27
- **Revenue (yearly):** ₹3211 Cr
- **Net Income:** ₹721.6 Cr
- **EBITDA:** ₹1108.5 Cr
- **52-Week High:** ₹1933
- **52-Week Low:** ₹1262
- **RSI (14):** 50.85

## Tapetide Score

- **Score:** 60 / 100
- **Score date:** 2026-09-04
- **Archetype:** Priced for Perfection
- **What it means:** The business scores well but the multiple leaves little room for error. The debate here is about the price, not the company; small disappointments tend to cost more at rich valuations.
- **Pillar profile:** Quality: Good · Valuation: Expensive · Momentum: Rising
- **Percentile:** 87.9 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 54.85 | 9% |
| growth | 59.21 | 9% |
| momentum | 85.44 | 12% |
| ownership | 58.65 | 24% |
| quality | 82.99 | 22% |
| valuation | 29.06 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has delivered good profit growth of 34.2% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 33.1%

### Weaknesses

- Stock is trading at 10.7 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 111.89% | 221.11% | 189.03% |
| ebitda margin growth | -1.47% | 15.37% | 14.46% | -14.85% |
| net income growth | -5.97% | 48.45% | 30% | 34% |
| revenue growth | 4.27% | 18.79% | 46% | 42% |
| roce | -1.73% | 7.53% | 31.83% | 32.06% |
| roe | -5.94% | -5.12% | 28.31% | -28.42% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 567 | 620 | 640 | 643 | 657 | 724 | 740 | 781 | 815 | 858 | 894 |
| Expenses | 405 | 494 | 467 | 454 | 476 | 498 | 502 | 511 | 536 | 563 | 604 |
| Operating Profit | 162 | 126 | 173 | 189 | 181 | 226 | 238 | 270 | 279 | 295 | 290 |
| OPM % | 29 | 20 | 27 | 29 | 28 | 31 | 32 | 35 | 34 | 34 | 32 |
| Other Income | 6 | 15 | 4 | 5 | 27 | 3 | 3 | 4 | 6 | 5 | 6 |
| Interest | 26 | 32 | 26 | 22 | 21 | 21 | 18 | 16 | 23 | 13 | 10 |
| Depreciation | 19 | 27 | 28 | 28 | 28 | 28 | 28 | 30 | 32 | 34 | 34 |
| Profit before tax | 124 | 81 | 122 | 144 | 160 | 180 | 195 | 228 | 229 | 253 | 251 |
| Tax % | 18 | 21 | 22 | 21 | 19 | 18 | 22 | 21 | 20 | 19 | 23 |
| Net Profit | 102 | 64 | 95 | 113 | 130 | 148 | 152 | 181 | 183 | 206 | 194 |
| EPS in Rs | 5.94 | 3.72 | 5.57 | 6.59 | 7.56 | 8.61 | 8.83 | 10.53 | 10.68 | 12 | 11.29 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 529 | 553 | 764 | 1031 | 1818 | 2664 | 3194 | 3347 |
| Expenses | 367 | 348 | 466 | 639 | 1297 | 1893 | 2110 | 2213 |
| Operating Profit | 162 | 205 | 298 | 392 | 521 | 771 | 1084 | 1134 |
| OPM % | 31 | 37 | 39 | 38 | 29 | 29 | 34 | 34 |
| Other Income | 31 | 16 | 1 | -2 | 40 | 39 | 17 | 20 |
| Interest | 7 | 8 | 7 | 6 | 61 | 91 | 72 | 62 |
| Depreciation | 40 | 30 | 23 | 25 | 59 | 113 | 124 | 131 |
| Profit before tax | 145 | 183 | 269 | 359 | 442 | 606 | 905 | 961 |
| Tax % | 5 | 9 | 13 | 15 | 16 | 20 | 20 | — |
| Net Profit | 137 | 165 | 233 | 305 | 370 | 486 | 722 | 764 |
| EPS in Rs | 166.73 | 200.1 | 13.61 | 17.86 | 21.68 | 28.33 | 42.03 | 44.5 |
| Dividend Payout % | 0 | 12 | 393 | 55 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 8 | 8 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 275 | 449 | 630 | 812 | 1141 | 1773 | 2783 |
| Borrowings | 0 | 76 | 65 | 52 | 1311 | 856 | 753 |
| Other Liabilities | 151 | 53 | 75 | 107 | 411 | 274 | 605 |
| Total Liabilities | 434 | 586 | 788 | 988 | 2880 | 2919 | 4158 |
| Fixed Assets | 36 | 87 | 76 | 59 | 1833 | 1790 | 1942 |
| CWIP | 0 | 0 | 0 | 0 | 3 | 13 | 6 |
| Investments | 1 | 14 | 16 | 32 | 195 | 114 | 377 |
| Other Assets | 397 | 485 | 695 | 898 | 849 | 1003 | 1832 |
| Total Assets | 434 | 586 | 788 | 988 | 2880 | 2919 | 4158 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 163 | 175 | 233 | 288 | 210 | 318 | 674 |
| Cash from Investing Activity | -79 | -167 | -82 | -158 | -1137 | 241 | -222 |
| Cash from Financing Activity | -41 | -37 | -59 | -152 | 780 | -389 | -412 |
| Net Cash Flow | 43 | -28 | 92 | -22 | -147 | 170 | 39 |
| Free Cash Flow | 152 | 168 | 222 | 280 | 177 | 276 | 614 |
| CFO/OP | 118 | 100 | 93 | 93 | 58 | 56 | 80 |

### Ratios

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 51 | 49 | 46 | 57 | 73 | 73 | 65 |
| Cash Conversion Cycle | 51 | 49 | 46 | 57 | 73 | 73 | 65 |
| Working Capital Days | 20 | 41 | 15 | 21 | -75 | 10 | -31 |
| ROCE % | — | 47 | 47 | 50 | 30 | 27 | 32 |

## Shareholding Pattern

### Quarterly

| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 63.72% | 63.72% | 63.72% | 63.72% | 63.72% | 63.72% | 63.72% |
| FIIs | 5.48% | 5.39% | 6.5% | 7.02% | 7.56% | 8.19% | 8% |
| DIIs | 4.45% | 4.03% | 4.33% | 4.89% | 6.06% | 6.4% | 7.5% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 10.25% | 10.93% | 10.81% | 10.83% | 10.33% | 10.22% | 9.98% |
| Others | 16.1% | 15.93% | 14.64% | 13.53% | 12.33% | 11.46% | 10.8% |
| No. of Shareholders | 109 | 57714 | 59218 | 57577 | 60788 | 60385 | 63025 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Sell
- **Buy / Neutral / Sell:** 6 / 6 / 7

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 1759.59 | Sell |
| EMA (10) | 1766.98 | Sell |
| SMA (20) | 1775.61 | Sell |
| EMA (20) | 1773.02 | Sell |
| SMA (50) | 1810.64 | Sell |
| EMA (50) | 1771.58 | Sell |
| SMA (100) | 1732.18 | Buy |
| EMA (100) | 1730.24 | Buy |
| SMA (200) | 1646.81 | Buy |
| EMA (200) | 1677.28 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 43.5 | Neutral |
| MACD (12,26,9) | -8.4 | Buy |
| Stochastic (14,3,3) | 43.85 | Neutral |
| ADX (14) | 12.61 | Neutral |
| Williams %R (14) | -79.18 | Neutral |
| ATR (14) | 53.37 | High Volatility |
| ROC (12) | -0.05 | Sell |
| Stoch RSI (14) | 17.59 | Buy |
| UO (7,14,28) | 39.04 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 6 | 75% |
| Hold | 2 | 25% |
| Sell | 0 | 0% |

Based on 8 analyst ratings, observed at 2026-09-11T04:35:01.885475+00:00.

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-04 | [Announcement under Regulation 30 (LODR)-Change in Management](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8832b771-b5b6-45e6-a6fd-aa5cb83a00a2.pdf) |
| 2026-08-29 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=56a38bd5-a7fb-4764-95dd-dd8e529af434.pdf) |
| 2026-08-28 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4c975ef3-2868-424b-af12-ab6b87d128f6.pdf) |
| 2026-08-28 | [Notice Convening The 20Th Annual General Meeting (AGM)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9933b49a-a9ac-4c60-a2cd-688ffb6a7b2c.pdf) |
| 2026-08-28 | [Business Responsibility and Sustainability Reporting (BRSR)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fea8adaa-ee37-4c5e-83e3-b56be74f5320.pdf) |
| 2026-08-28 | [Letter Sent To Members.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7f0688ef-e62e-4acd-a2bc-4ecf478ed18a.pdf) |
| 2026-08-18 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bbaddf06-7e9f-4a51-b6d3-745976840a05.pdf) |
| 2026-08-13 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e34caf75-01ce-4cd2-a59a-eff15a76250b.pdf) |
| 2026-08-13 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=94d43cc0-e726-4fa5-bf81-b840f5957441.pdf) |
| 2026-08-11 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ddbb5fbd-85ae-452d-b0af-4c9e9545ddda.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-08-06 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=99cec7ff-776c-4767-bf64-b9aa37c4f2c4.pdf) |
| 2026-05-14 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6324925b-65e9-4b4c-a7ea-61826c255a57.pdf) |
| 2026-04-24 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b9854a0e-139c-4689-92b3-d79a831f7bfa.pdf) |
| 2026-02-05 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=911502fa-54fb-4670-a289-07b114731e20.pdf) |
| 2025-10-31 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0d7c3bfd-f438-467e-8e39-8173b16c1e07.pdf) |
| 2025-08-01 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=171d8a76-6ad8-4eec-ac64-eb244f5dd70a.pdf) |
| 2025-07-09 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2a9ef6a0-1c0b-4499-90d2-f6b66a2f0252.pdf) |
| 2025-07-03 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=178366c2-3460-45ea-b67d-a68b91a5367c.pdf) |
| 2025-05-16 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3db76cd8-0f49-4425-bf68-13dfb64a1295.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-08-05 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0b4bf5c0-5abc-4633-8010-c0edd6be884c.pdf) |
| 2026-05-13 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=da1c9a39-2985-42fd-8cce-9433ce3dde71.pdf) |
| 2026-04-24 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2a38e8b8-6f98-4816-b3a2-e7229525227d.pdf) |
| 2026-04-23 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=28cb4422-c390-4f7c-aca3-6ca2abc0cc7d.pdf) |
| 2026-04-23 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d7c5e01b-d511-4708-85c1-ec581180a313.pdf) |
| 2026-02-04 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4bba296e-86d7-4511-a08c-ca85044d1572.pdf) |
| 2025-10-30 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6d5178d5-8bcf-4188-8f44-5171eea17f7b.pdf) |
| 2025-07-31 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2024dd9d-338c-4225-8094-e59e54135e94.pdf) |
| 2025-07-03 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8f181650-afbc-421f-af1e-f3659e2d97ee.pdf) |
| 2025-05-15 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0a96741f-5403-4759-9ee1-cb3bcb36d36e.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-05 | [Results - The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=312bbb5b-2fc6-486d-b44c-be1a08e66ef6.pdf) |
| 2026-05-13 | [The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ended March 31 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d16d99b0-14e6-4393-b8fd-c1fecdb2f0dc.pdf) |
| 2026-02-04 | [Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c807763b-8355-45a8-aa98-9b663ca09a6d.pdf) |
| 2025-10-30 | [Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8b8075c5-9a0d-42e7-93d2-f93fab7aeeee.pdf) |
| 2025-07-31 | [Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Outcome Of The Board Meeting Held On July 31 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2901bdad-cc33-48d7-baf0-e095b09d489e.pdf) |
| 2025-05-15 | [The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ended March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b2c1cd51-80b7-47c6-9151-04dc735b2508.pdf) |
| 2025-02-05 | [Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2024.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d33c0756-64b8-434c-9ddd-f417794ba60d.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-05-20 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b4e56003-3feb-4c67-bf97-0f22ac6106eb.pdf) |
| 2026-02-11 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=826a5576-6f9c-4b10-a23e-f03eab79ebfd.pdf) |
| 2025-11-06 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e3930a45-8d1c-461d-9cd1-fff61d0b976c.pdf) |
| 2025-08-06 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c4599db9-1843-407b-97e9-ba744c5f28e8.pdf) |
| 2025-05-22 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d09a7ba0-d141-4fe7-ba71-2d62f957c848.pdf) |
| 2025-02-12 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3893f5a3-e337-4adb-9d3e-41a08802b628.pdf) |
| 2025-02-06 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8217a56f-798b-4833-8726-3f187adf2f3f.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 8h - IKS Health agrees to acquire TruBridge for $26.25 per share; closing expected in Q3 2026. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 8h - IKS Health agrees to acquire TruBridge for $26.25 per share; closing expected in Q3 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/d312e066-85e9-47cd-a46c-9a49283783a9.pdf) |
| 7 Apr - IKS Health launches audit-ready autonomous coding engine with up to 95% accuracy and Epic integration. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 7 Apr - IKS Health launches audit-ready autonomous coding engine with up to 95% accuracy and Epic integration.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c118b281-dcb0-4866-8074-d2eac41c3b93.pdf) |
| 5h - IKS Health agreed to acquire TruBridge for $26.25/share; closing expected in Q3 2026. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 5h - IKS Health agreed to acquire TruBridge for $26.25/share; closing expected in Q3 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/79dd9f2d-5eeb-4ead-abcc-bb32aa82ca9f.pdf) |
| 5 May - IKS Health announces multi-year partnership with Holyoke Medical Center on May 5, 2026. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 5 May - IKS Health announces multi-year partnership with Holyoke Medical Center on May 5, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/a7b62bcc-2fd0-4105-a228-03d4dd33f564.pdf) |
| 5 May - Board meets May 13, 2026 to approve audited Q4 and FY26 financial results; trading window closed till May 15. | [Board Meeting Intimation for Considering And Approving The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Year Ended March 31, 2026. 5 May - Board meets May 13, 2026 to approve audited Q4 and FY26 financial results; trading window closed till May 15.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/806f78d7-9f28-402f-a672-01fe9e8f0a3d.pdf) |
| 5 Mar - Grant of 600,000 ESOPs on March 5, 2026 at Rs.1,331 exercise price. | [Grant Of Employee Stock Options Under Employee Stock Option Plan 2022 5 Mar - Grant of 600,000 ESOPs on March 5, 2026 at Rs.1,331 exercise price.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d0840860-e032-42bb-8c93-c10fea85c151.pdf) |
| 31 Mar - IKS Health acquihires ThinkDTM; Tij Bedi joins as EVP & GM Patient Access and Innovation (announced March 31, 2026). | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 31 Mar - IKS Health acquihires ThinkDTM; Tij Bedi joins as EVP & GM Patient Access and Innovation (announced March 31, 2026).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/730b36f7-cf65-47e5-a280-b5486210f096.pdf) |
| 2d - Q4 FY2025-26 earnings conference call scheduled for May 14, 2026 at 8:30 AM IST. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 2d - Q4 FY2025-26 earnings conference call scheduled for May 14, 2026 at 8:30 AM IST.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/8c461cb1-fa44-416d-9dd9-903465d082ed.pdf) |
| 29 Apr - Transcript of Conference Call held on April 24, 2026. | [Announcement Under Regulation 30 (LODR)-Conference Call Transcript 29 Apr - Transcript of Conference Call held on April 24, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/03f6fb92-01df-4094-a8d8-efdb31c50080.pdf) |
| 29 Apr - Transcript of Conference Call held on April 24, 2026. | [Announcement Under Regulation 30 (LODR)-Conference Call Transcript 29 Apr - Transcript of Conference Call held on April 24, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/03f6fb92-01df-4094-a8d8-efdb31c50080.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e3930a45-8d1c-461d-9cd1-fff61d0b976c.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b4e56003-3feb-4c67-bf97-0f22ac6106eb.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/b4e56003-3feb-4c67-bf97-0f22ac6106eb.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d09a7ba0-d141-4fe7-ba71-2d62f957c848.pdf) |
| Jul 2025 | [Concall - Jul 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2a9ef6a0-1c0b-4499-90d2-f6b66a2f0252.pdf) |
| Feb 2025 | [Concall - Feb 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3893f5a3-e337-4adb-9d3e-41a08802b628.pdf) |
| Aug 2025 | [Concall - Aug 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c4599db9-1843-407b-97e9-ba744c5f28e8.pdf) |
| Apr 2026 | [Concall - Apr 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/28cb4422-c390-4f7c-aca3-6ca2abc0cc7d.pdf) |
| Apr 2026 | [Concall - Apr 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d7c5e01b-d511-4708-85c1-ec581180a313.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0d11e35c-d688-47ac-908b-5db81932ab7e.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:26:43.056Z.